Toward a Single-Dose Cure for Buruli Ulcer-Reference-Cited by-同舟云学术

Toward a Single-Dose Cure for Buruli Ulcer

Published:2020-08-20 Issue:9 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Thomas Sangeeta S.¹²,Kalia Nitin Pal²³,Ruf Marie-Thérèse⁴⁵,Pluschke Gerd⁴⁵,Pethe Kevin²⁶^ORCID

Affiliation:

1. NTU Institute for Health Technologies (HealthTech NTU), Interdisciplinary Graduate Programme, Nanyang Technological University, Singapore

2. Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore

3. Clinical Microbiology Division, CSIR-IIIM, Jammu and Kashmir, India

4. Swiss Tropical and Public Health Institute, Basel, Switzerland

5. University of Basel, Basel, Switzerland

6. School of Biological Sciences, Nanyang Technological University, Singapore

Abstract

A single dose of Q203 (Telacebec), a phase 2 clinical candidate for tuberculosis, eradicates Mycobacterium ulcerans in a mouse model of Buruli ulcer infection without relapse up to 19 weeks posttreatment. Clinical use of Q203 may dramatically simplify the clinical management of Buruli ulcer, a neglected mycobacterial disease.

Funder

MOH | National Medical Research Council

National Research Foundation Singapore

NTU | Lee Kong Chian School of Medicine, Nanyang Technological University

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00727-20

Reference17 articles.

1. Buruli Ulcer, a Prototype for Ecosystem-Related Infection, Caused by Mycobacterium ulcerans

2. Increased Severity and Spread ofMycobacterium ulcerans, Southeastern Australia

3. World Health Organization. 2012. Treatment of Mycobacterium ulcerans disease (Buruli ulcer): guidance for health workers. World Health Organization, Geneva, Switzerland.

4. Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial

5. Burden of Mycobacterium ulcerans Disease (Buruli Ulcer) and the Underreporting Ratio in the Territory of Songololo, Democratic Republic of Congo

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Review of Antibacterial Candidates with New Modes of Action;ACS Infectious Diseases;2024-07-17

2. Unlocking Opportunities for Mycobacterium leprae and Mycobacterium ulcerans;ACS Infectious Diseases;2024-01-31

3. How our molecular understanding of the pathogenesis of Mycobacterium ulcerans infection can improve diagnosis of Buruli ulcer;Expert Review of Molecular Diagnostics;2023-12-11

4. Key Contributions by the Swiss Tropical and Public Health Institute Towards New and Better Drugs for Tropical Diseases;CHIMIA;2023-09-20

5. Repurposing of Tuberculosis Drug Candidates for the Treatment of Mycobacterium ulcerans Disease;CHIMIA;2023-09-20